Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D004343:Drug Implants; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D018931:Antineoplastic Agents, Hormonal; D004343:Drug Implants; D016729:Leuprolide